Last reviewed · How we verify
NCT03536936: OPAMA
Oxygenation and Perfusion in Patients With Acute Migraine Attacks
trial in Migraine in 1,000 participants. Completed in 30 April 2018.
30 April 2018
Quick facts
| Lead sponsor | Insel Gruppe AG, University Hospital Bern |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 January 2010 |
| Primary completion | 30 April 2018 |
| Estimated completion | 30 April 2018 |
Conditions studied
- Migraine — all drugs for Migraine →
- Migraine With Aura — all drugs for Migraine With Aura →
- Migraine; Status — all drugs for Migraine; Status →
Sponsor
Insel Gruppe AG, University Hospital Bern
Who can join
Adults 6 to 80, any sex, with Migraine or Migraine With Aura. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to retrospectively evaluate brain perfusion and oxygenation in acute migraine attacks. Magnetic resonance perfusion and susceptibility weighted imaging are the technics to measure perfusion and oxygenation respectively.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03536936
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Migraine
Currently open trials in the same condition.
- NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
- NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
- NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
- NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
- NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting
Other Insel Gruppe AG, University Hospital Bern trials
Trials by the same sponsor.
- NCT06546384 — GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease · NA · not yet recruiting
- NCT07524049 — Giving Children a Voice in Paediatric Anaesthesia · not yet recruiting
- NCT07415668 — Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning · NA · not yet recruiting
- NCT07478536 — Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) · not yet recruiting
- NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03536936 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern
- Last refreshed: 25 May 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03536936.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing